Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The RAS oncogene (MIM 190020) is mutated in nearly one-third of all human cancers. Additionally we are shipping RASSF3 Antibodies (60) and many more products for this protein.
Showing 6 out of 7 products:
Taken together, these findings indicate that the RASSF3 (show RASSF5 Proteins) promoter rs6581580 T>G SNP is potentially functional, modulating susceptibility to SCCHN among non-Hispanic whites.
hypermethylation-induced RASSF3 (show RASSF5 Proteins) silencing plays an important role in the tumorigenesis of pituitary somatotroph adenomas.
tumor suppressor activity of RASSF3 (show RASSF5 Proteins), which occurs through p53 (show TP53 Proteins) stabilization and regulation of apoptosis and the cell cycle.
Mammary tumor incidence in bi-transgenic mice is delayed, suggesting that transgenic Rassf3 (show RASSF5 Proteins) may influence mammary tumor incidence in transgenic mice
The presence of a Ras association domain common to NORE1 (show RASSF5 Proteins),RASSF1 (show RASSF1 Proteins), and RASSF3 (show RASSF5 Proteins) suggests their possible involvement inRas-like signaling pathways.
The RAS oncogene (MIM 190020) is mutated in nearly one-third of all human cancers. Members of the RAS superfamily are plasma membrane GTP-binding proteins that modulate intracellular signal transduction pathways. A subfamily of RAS effectors, including RASSF3, share a RAS association (RA) domain.
Ras association (RalGDS/AF-6) domain family member 5
, Ras association (RalGDS/AF-6) domain family member 3
, Ras association (RalGDS/AF-6) domain family 3
, Ras association (RalGDS/AF-6) domain family 5
, ras association domain-containing protein 3
, Ras association domain family 3
, novel ras effector 1